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Background: A retrospective study of the clinicopathological features of presumed and confirmed cases of
idiopathic inflammatory polymyopathy in the Hungarian Vizsla dog and guidelines for breeding.
Results: 369 medical records were reviewed (1992–2013) and 77 Hungarian Vizslas were identified with a case
history consistent with idiopathic inflammatory polymyopathy. Inclusion criteria were: group 1 (confirmed diagnosis);
histopathology and clinical findings compatible with an inflammatory polymyopathy and group 2 (probable diagnosis);
clinical findings compatible with a polymyopathy including dysphagia, sialorrhea, temporal muscle atrophy, elevated
serum creatine kinase (CK) activity, and sufficient clinical history to suggest that other neuromuscular disorders could be
ruled out. Some group 2 dogs had muscle biopsy, which suggested muscle disease but did not reveal an inflammatory
process. The mean age of onset was 2.4 years; male dogs were slightly overrepresented. Common presenting signs
were dysphagia, sialorrhea, masticatory muscle atrophy, and regurgitation. Common muscle histopathological findings
included degenerative and regenerative changes, with multifocal mononuclear cell infiltration with lymphoplasmacytic
myositis of variable severity. A positive response to immunosuppressive treatment supported an immune-mediated
aetiology. The mean age at death and survival time were 6.4 and 3.9 years, respectively. Recurrence of clinical signs
and aspiration pneumonia were common reasons for euthanasia.
Conclusions: Diagnosis of Vizsla idiopathic inflammatory polymyopathy can be challenging due to lack of specific
tests, however the presence of dysphagia, regurgitation and masticatory muscle atrophy in this breed with negative
serological tests for masticatory muscle myositis and myasthenia gravis, along with muscle biopsies suggesting an
inflammatory process, support the diagnosis. However, there is an urgent need for a more specific diagnostic test.
The average of inbreeding coefficient (CoI) of 16.3% suggests an increased expression of a Dog Leukocyte Antigen
Class II haplotype, leading to an increased disease risk. The prognosis remains guarded, as treatment can only
manage the disease. Recurrence of clinical signs and perceived poor quality of life are the most common reasons
for humane euthanasia.
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The immune-mediated inflammatory myopathies are ac-
quired diseases, characterised by immunological processes
primarily involving the skeletal muscle. In human medi-
cine these disorders are divided into five major subsets:
dermatomyositis, generalised polymyositis, focal myositis,
necrotizing autoimmune myositis and inclusion-body
myositis [1]. All but necrotising autoimmune myositis* Correspondence: Annat@Fitzpatrickreferrals.co.uk
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unless otherwise stated.have been described in canine medicine. Dermatomyositis
affects skin and muscle and is a complement-mediated
microangiopathy in which complement deposition in
small vessels leads to vascular damage and muscle ischae-
mia [2]. Canine dermatomyositis is an autosomal domin-
ant condition with incomplete penetrance recognised in
rough collies, Shetland sheepdogs and Pembrokeshire
corgis [3,4]. In generalised polymyositis and inclusion-
body myositis, muscle fibres expressing antigens of the
major histocompatibility complex (MHC) are infiltrated
by cytotoxic T cells, leading to myofibre necrosis [2,5,6].
In contrast to man, inclusion body myositis is recognisedhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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inclusion body myositis is characterised by cytoplasmic
filamentous inclusions, membranous structures and mye-
loid bodies, in addition to cellular infiltration and in-
creased expression of MHC antigen [7].
Focal myositis is characterised by immune-mediated
damage of specific muscle groups such as the masticatory
muscles (e.g. temporalis, masseter, pterygoid, rostral por-
tion of the digastricus) in masticatory muscle myositis
(MMM) and the extraocular muscles in extraocular
myositis. MMM is characterised by the presence of
muscle-specific serum autoantibodies, most notably
against masticatory myosin binding protein-C [8].
Polymyositis has been described previously in many
breeds although large breed dogs are predisposed, es-
pecially Boxers, German shepherd dogs, Labrador and
Golden retrievers, Doberman pinchers, and Newfound-
lands [6,9-11]. A breed-specific idiopathic inflammatory
polymyopathy has been described previously in dogs of
the Hungarian Vizsla breed [12,13] and is characterised
by cellular infiltration, particularly affecting masticatory
and pharyngeal-oesophageal muscles.Table 1 Clinical and diagnostic findings in Vizsla polymyopat
Clinical and Diagnostic Findings in VIP Number of
dogs from
Group 1
% of total
Group 1
dogs (24)
N
do
G
Dysphagia (pharyngeal phase of deglutition) 20 83% 49
Drinking and eating difficulties (Oral phase of
deglutition)
21 87% 48
Sialorrhea 21 87% 46
Masticatory muscle atrophy 20 83% 45
Regurgitation 19 79% 42
Trismus 3 12% 13
Masticatory myalgia 1 4% 8
Aspiration pneumonia 4 17% 13
Toxoplasma gondii serumantibody titre (tested
for and negative)
14 58% 11
Neospora caninum serum antibody titre (tested
for and negative)
15 62% 10
Elevated serum creatine kinase (>190 IU/L) 18 75% 23
Serum creatine kinase >1000 11 46% 14
Anti- 2 M antibody titre (Tested for and negative) 12 50% 17
Anti-acetylcholine receptor antibody titre (Tested
for and negative)
16 67% 16
Electromyography (Performed and findings
suggestive of myopathy)
15 62% 5
Electromyography (Performed and findings
normal)
1 4% 2
Modality by which diagnosis
Megaoesophagus was made
Radiographs 8 33% 18
Barium 1 4% 9
Fluoroscopy 4 17% 8The aim of this study was to describe the clinicopatho-
logical features of idiopathic inflammatory polymyopathy
in the Hungarian Vizsla, in particular to emphasise the
diagnostic approach, treatment, outcome, and to recom-
mend guidelines for breeding practices.
Results
Signalment and clinical signs
Seventy-seven of the 369 Hungarian Vizsla dogs (Tables 1
and 2) were determined to have a case history consistent
with Vizsla idiopathic inflammatory polymyopathy (VIP)
(Group 1, n = 24 dogs; Group 2, n = 53 dogs including
eight dogs with biopsy-confirmed non-inflammatory
muscle disease). Two cases were shown to have acetyl-
choline receptor antibodies (consistent with myasthenia
gravis) and they were excluded from the study. Eight of
the 77 affected cases were from outside Europe: three
were from USA, one was from New Zealand, and four
were from Australia. The mean age of onset was 2.4 years
(range 0.2–10.3 years). Male dogs were slightly overrep-
resented (entire male:neutered male:entire female:neu-
tered female 26:24:9:17). In one case the gender washy
umber of
gs from
roup 2
% of total
Group 2 (53)
Total number of CASES with this
clinical signs or had this diagnostic
test out of total 77 dogs
% of total
cases (77)
92% 69 90%
91% 69 90%
87% 67 87%
85% 65 84%
79% 61 79%
25% 16 21%
15% 9 12%
25% 17 22%
21% 25 32%
19% 25 32%
43% 41 53%
26% 25 32%
32% 29 38%
30% 32 42%
9% 20 26%
4% 3 4%
34% 26 34%
17% 10 13%
15% 12 16%
Table 2 Clinical signs of idiopathic inflammatory
polymyopathy in the Vizsla – Percentage of dogs with
this clinical sign is indicated (both Group 1 and 2
combined)
Clinical signs in VIP
Most common Less common
Dysphagia (pharyngeal phase) 90% Other muscle atrophy 43%
Drinking/Eating difficulty
(oral phase)
90% Exercise intolerance 35%
Sialorrhea 87% Weakness 30%
Masticatory muscle atrophy 84% Trismus 21%
Regurgitation 79% Lameness 19%
Masticatory myalgia 12%
Figure 2 Masticatory muscle atrophy in VIP.
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groups (Tables 1 and 2) were dysphagia (i.e. pharyngeal
phase of deglutition) (Additional file 1: Video 1) (90% of
all dogs; group 1: 83% and group 2: 92%), difficulty in eat-
ing and drinking (i.e. oral phase of deglutition) (Additional
file 2: Video 2) (90% combined; group 1: 87% and group 2:
91%), sialorrhea (87% of all dogs; group 1: 87% and group
2: 87%) (Figure 1) and regurgitation (79% of all dogs;
group 1: 79% and group 2: 79%). Pain on opening the jaw
was reported in 12% of all dogs (group 1: 4% and group 2:
15%). Masticatory muscle atrophy (i.e. masseter, tempor-
alis and pterygoid muscles) (Figure 2) was present in 84%
of all dogs (group 1: 83% and group 2: 85%), and 21% of
all dogs had restricted jaw motility (group 1: 12% and
group 2: 25%). Masticatory muscle atrophy either ap-
peared early in the course of the disease, or had a more in-
sidious onset, progressing slowly over several months or
years (Figure 3). Enophthalmos, if present, was secondary
to atrophy of the pterygoid muscle. Generalised muscle at-
rophy (43% of all dogs; group 1: 38% and Group 2: 45%),
exercise intolerance (35% of all dogs; group 1: 46% andFigure 1 Sialorrhoea in VIP.group 2: 30%), generalised weakness (30% of all dogs;
group 1: 38% and group 2: 26%), and lameness (19% of all
dogs; group 1: 21% and group 2: 19%) were less common
signs. Three cases had dysuria (two in group 1 and one in
group 2). The owners described a “stop-start flow” as if
the dogs had difficulty maintaining a urine stream. The
underlying pathophysiology for this was not ascertained.
In addition to clinical signs of neuromuscular disease,
25 dogs (seven in group 1, 18 in group 2) had other co-
morbidities either concurrently or at some other stage in
their life, including other inflammatory diseases (Table 3):
17 dogs with atopic dermatitis; two dogs with immune-
mediated polyarthritis; nine dogs with inflammatory bowel
disease; three dogs with keratoconjunctivitis sicca; one
dog with sebaceous adenitis; one dog with steroid-
responsive meningitis arteritis. There were also three dogs
with idiopathic epilepsy, one dog with a fly-catching re-
petitive behavioural disorder and one dog with splenic
haemangiosarcoma. Fourty dogs were dead at the time of
writing and dysphagia and aspiration pneumonia were re-
ported to be the main cause of death.
Laboratory findings
A summary of the diagnostic tests performed in each dog
is detailed in Table 1 and more detailed results are avail-
able in Additional file 3. Serum CK activity was evaluated
in 47/77 of cases and it was elevated (>190 IU/L) in 87%
and above 1000 IU/L in 53%. In four cases the result was
unknown. Serology for determination of antibodies against
2 M fibres for masticatory muscle myositis (MMM) or for
antibodies against acetylcholine receptors for MG was
Figure 3 Hungarian Vizsla dog before and after VIP.
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for MMM was negative in all cases tested; two dogs were
positive for MG and were excluded from this study. Ser-
ology for protozoal diseases causing inflammatory myop-
athy (Toxoplasma gondii and Neospora caninum serum
antibody titres) was negative in 25 cases. Imaging tech-
niques were performed in 52 cases. As part of the diag-
nostic work up for regurgitation, 28/77 of the dogs had
oesophagogastroduodenoscopy. This investigation re-
vealed the presence of Helicobacter spp. in two dogs and
biopsy evidence suggestive of inflammatory bowel disease
(IBD) in nine dogs. Thoracic radiographs confirmed mega-
oesophagus in 28 dogs (Figure 4) and aspiration pneumo-
nia in 17 dogs (Figure 5). A barium study was performed
in 10 cases; however, this test was not superior to plain
radiography in proving oesophageal dysfunction. Fluoros-
copy was performed in 12 cases where routine radiog-
raphy with or without barium had not proved oesophageal
dysfunction and in three dogs dysmotility, mainly involv-
ing the oral and pharyngeal phase, was demonstrated.
Electromyography (EMG) of the appendicular and axial
muscles including the masticatory muscles showed ge-
neralised abnormal spontaneous activity in 20 of 23 dogs,
including positive sharp waves, fibrillation potentials, pro-
longed insertional activity, and occasional pseudomyotonia.
EMG also confirmed tongue and pharyngeal involvement
in 11 of 23 dogs. Magnetic Resonance Imaging (MRI) of
the head was performed in five cases, and in two dogs it
revealed changes within the masticatory muscle consistentTable 3 Other idiopathic immune-mediated diseases seen
in the dogs in this series
Concurrent immune-mediated diseases reported
in the dogs in this series with VIP
Number of dogs
Atopic dermatitis 17
Immune-mediated polyarthritis (IMP) 2
Inflammatory bowel disease (IBD) 9
Keratoconjunctivitis sicca 3
Sebaceous adenitis (SA) 1
Steroid-responsive meningitis arteritis (SRMA) 1with a multifocal inflammatory process. Identification of
this change suggested a suitable biopsy site where clinical
examination and other diagnostic tests such as EMG had
not confirmed a diagnosis or the focal location of the path-
ology (Figure 6).
Muscle biopsy samples were taken in 36 of the 77 cases
(37%) (Table 4); however, in seven cases the biopsy reports
were not included in the case notes. In twenty-five of the
29 dogs for which histology was available, the biopsies
were taken from the most accessible sites such as mas-
seter, temporalis, lingual, triceps and cranial tibialis mus-
cles, while in four cases the biopsy location was not
reported. In 20 of the 25 dogs underwent biopsy following
EMG or MRI identification of the most potentially useful
sites. Post-mortem examinations were performed in four
of the 40 deceased dogs and besides being a valuable aid
towards confirming the diagnosis with multifocal lympho-
plasmacytic and macrophagic cellular infiltrations having
an endomysial and perimysial distribution with invasion of
non-necrotic fibres being the most common histopatho-
logical finding in both ante and post mortem samples. In
addition, in one case post-mortem examination revealed
the presence of lymphoid cell infiltrate in the oesophagealFigure 4 Left lateral thoracic view, showing megaoesophagus.
Figure 5 Left lateral thoracic view, showing aspiration pneumonia.
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glion cells (Table 3). Degenerative (e.g. variation in myofi-
bre size, myofibre hyalinisation, necrosis, angular atrophy,
nuclear internalisation, granular sarcoplasm, sarcolemmal
fragmentation) and regenerative changes (e.g. cytoplasmic
basophilia, nuclear rowing, presence of type 2C fibres,
compensatory hypertrophy) were found variably (Figure 7).
Myofibre loss, endomysial fibrosis and excessive peri-
mysial fatty tissue were also found (Table 4). The presence
of the adipose tissue was considered likely to be secondary
to chronic injury as fat infiltration has been reported in
chronically denervated muscles, but may also occur in se-
vere chronic degenerative myopathy [14]. In 7/32 cases
there was an absence of inflammatory changes. This wasFigure 6 Transverse T1–weighted post-gadolinium contrast image at
the level of the optic chiasm. Patchy up take of contrast is present within
the right temporal muscle (arrow) suggesting an inflammatory process.probably associated with recent steroid therapy (in two
cases) or end-stage disease. However, in three dogs with
recent onset disease that had not been treated, there was a
degenerative and regenerative myopathy in the absence of
obvious inflammatory change. In two cases antibodies
against endplate proteins (SPA-HRPO) were identified.
Management
Sixty-one of 77 of the cases were treated with
immune-suppressive doses of corticosteroids either as
a monotherapy (32/61) or in combination with other
immunosuppressive treatments (29/61). For the other 16
of 77 dogs, no treatment details were stated in the clinical
record. A combination of immunosuppressive agents was
considered preferable to reduce long-term corticosteroid
side effects and/or when the clinical response to mono-
therapy was poor. The most common polypharmacy was
prednisolone and azathioprine (25/29). Less commonly,
ciclosporin was used in combination with prednisolone
(2/29) or with both prednisolone and azathioprine (2/29).
Leflunomide was used as an adjunct drug in one case in
association with corticosteroids. Two cases were treated
with methotrexate, either with corticosteroids or in com-
bination with corticosteroids and azathioprine. The typical
initial glucocorticoid dose was 1-2 mg/kg prednisolone
twice a day, whilst azathioprine was used at 2 mg/kg or
50 mg/m2 once a day. Leflunomide was used at 4 mg/kg
once a day, while methotrexate was given at 2.5 mg/m2
twice a week. The dosages were then tapered based on the
response to treatment. Improvement of clinical signs espe-
cially sialorrhea, regurgitation, dysphagia was seen in 90%
of the treated dogs. Unfortunately, we were unable to
evaluate time frame to improvement due to lack of
detailed temporal data, however the use of anti-
inflammatory dose of corticosteroids or a rapid tapering
regimen with withdrawal of drugs within a 1-year period
appeared to be associated with earlier relapse and in-
creased mortality in 23% of the treated cases. Two dogs
treated with azathioprine had adverse gastrointestinal
effects (i.e. profound vomiting and occasional diarrhoea)
and exhibited marked elevation in serum hepatocellular
enzymes resulting in cessation of therapy. Ciclosporin was
discontinued in one case due to severe inappetence, while
the other three cases in which this drug was used had
undetermined clinical benefit. Corticosteroid side ef-
fects such polyphagia, polydipsia, polyuria, and iatro-
genic hyperadrenocorticism were found in 15% of the
treated cases. Supportive treatments including gas-
troprotectants and pro-kinetics were also commonly
prescribed such as omeprazole, sucralfate, cimetidine,
famotidine, ranitidine, maropitant, metoclopramide, ery-
thromycin (as a pro-kinetic at a dose of 0.5-1 mg/kg three
times a day), and cisapride. Three cases were treated
with phenobarbital on the initial assumption that their
Table 4 Histological changes in the 32 Hungarian Vizslas with biopsy-confirmed polymyopathy
Histopathological changes (Total 32) Group 1 Group 2
25 total dogs (biopsies) (confirmed VIP diagnosis) 7 dogs (3 biopsies, 1 biopsy and post-mortem/
3 post-mortem) (myopathy diagnosis)
Inflammatory change e.g. Lymphohistiocytic
inflammation
Variability in myofibres size with multifocal
endomysial, interstitial and perivascular mononuclear
cell infiltrations (lymphocytes & macrophages +/−
plasma cells, eosinophils) of non-necrotic fibres.
Underlying inflammatory process masked by
corticosteroid treatment in one case.
25 dogs 0 dogs
Myopathic change Variation in the myofibre size without
inflammatory infiltration.
0 dogs 7 dogs
Adipose tissue Small amount of adipose tissue associated with
fibrosis.
Adipocytes present in some fascicles
(endomysium and perimysium).
2 dogs 1 dogs
Fibrosis None OR perimisial/endomysial fibrosis OR
occasionally area of fibrosis with lack of myofibres
with any significant inflammation (primary or
secondary?)
3 dogs 0 dogs
Degenerative changes Either any appreciable myofibre degeneration or
active degenerative changes within the muscle
fibres (variation in myofibre diameter, atrophy with
round to polygonal/angular shape, hyalinisation,
nuclear internalisation, sarcolemmal fragmentation).
Variation in muscle fibres, atrophy (occasionally
smaller fibres grouped together, some angular
but most round to polygonal profile), nuclear
internalisation.
19 dogs 4 dogs
Regenerative changes Nuclear rowing, centralisation/hyperthrophy of the
nuclei increased cytoplasmic basophilia, type 2
fibres.
Occasional enlarged and round myofibres
(compensatory hypertrophy), and nuclear
rowing.
13 dogs 3 dogs
Necrotic fibres Scattered to severe necrotic myofibres with some
undergoing phagocytosis.
7 dogs 0 dogs
Fibrosis Mild to moderate endomysial and perimysial
fibrosis secondary to myofibre loss.
Increased endomysial and perimysial connective
tissue secondary to myofibre loss.
7 dogs 2 dogs
Intramuscular nerve branches Normal (25 dogs) Normal (7 dogs)
Immunoreagent SPA-HRPO Present in two cases
(Antibodies against endplate proteins)
Dystrophin protein Decreased staining for carboxy terminus of the
dystrophin protein was found in one case; however,
the dog improved on immunosuppressive
treatment and the suspicion for muscle dystrophy
was abandoned.
Tauro et al. BMC Veterinary Research  (2015) 11:97 Page 6 of 13diagnosis was phenobarbital-responsive hypersalivation,
but there was no clinical benefit reported. In the dogs with
dysuria, one dog was treated with 0.35 mg/kg diazepam
three times a day and the other with 1 mg/kg dantrolene
twice a day and 0.4 mg/kg phenoxybenzamine twice a day,
and both showed clinical improvement; the third dog was
treated with phenylpropanolamine at the dose of 0.8 mg/kg
once a day and diazepam at the dose of 0.25 mg/kg twice aday with no improvements, while corticosteroid therapy
was reported to be beneficial.
At the time of writing, 40 of 77 affected cases had died:
thirty-seven dogs were euthanised due to the disease and
three died of other causes including haemangiosarcoma,
idiopathic epilepsy and reported natural causes. The mean
age of death was 6.4 years (range 1.0 – 14.5 years), and the
mean survival time following diagnosis was 3.9 years
Figure 7 Histopathological section of temporal muscle (H&E stain, x100). Mild variation of myofibre size, with internal nuclei (black arrow) found
along the plane of the fibre splitting (star), hypertrophied myofibres (black arrow head), granular sarcoplasm (yellow star), angular atrophy (A), and
necrosis with infiltration of inflammatory cells (blue arrow head).
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and poor quality of life because of difficulty eating and
drinking were common reasons cited for euthanasia.
Discussion
This paper describes a myopathy in the Hungarian Vizsla
characterised by dysphagia, regurgitation, sialorrhea and
masticatory muscle atrophy, which is responsive to im-
munosuppression in the majority of cases. Biopsy sam-
pling in a proportion of cases suggested an idiopathic
inflammatory polymyopathy. One of the authors (CR) first
diagnosed idiopathic inflammatory polymyopathy in a
Hungarian Vizsla in 1994, but anecdotal reporting by
owners suggests that the disease has been a problem in
the breed since the early 1980s or before. A serious short-
coming in this retrospective study was the inclusion of
non-biopsy confirmed cases. However, group 2 dogs were
included because excluding them might give the errone-
ous impression that this syndrome can be easily diagnosed
by biopsy and exclusion of these cases would also lose
clinical data that might be valuable to practising clinicians.
Moreover, it is possible that this syndrome might actually
represent a collection of immune-mediated diseases in the
Hungarian Vizsla with a common theme of dysphagia, re-
gurgitation and masticatory muscle atrophy; so although
biopsy remains the gold standard for diagnosis, it was not
always useful and in seven cases the muscle biopsies did
not confirm an inflammatory process despite using EMG
in two of these cases to direct biopsy and the dogs subse-
quently responding to immunosuppressive therapy. Post-
mortem was performed in four of these seven cases withsuspicion of VIP and in two of them the disease was con-
firmed. This finding, and the differences between VIP and
the classical description of canine polymyositis [9] (in par-
ticular dysphagia), raises the question as to whether the
pathogenesis is different. Diagnosis of typical myositis in
man is dependent on the presence of inflammatory infil-
trates and positive human leukocyte antigen (HLA – ABC)
labelling of the sarcolemma. However, other immune-
mediated myopathies exist, e.g. human necrotising myop-
athy has no inflammatory infiltrates which is associated
with anti-signal recognition particle autoantibodies. Dys-
phagia is an important clinical feature of this disease and
patients respond to immunosuppression [15]. A future
goal to improve diagnosis of VIP is to investigate whether
or not it is possible to identify myositis-specific auto-
antibodies. In the present study, incubation with staphylo-
coccal protein A conjugated to horseradish peroxidase
(SPA-HRPO) detected antibody (IgG) bound to the neuro-
muscular junction in two group 1 cases. This labelling was
suggestive of an autoimmune polymyositis. In the present
study, nine out of 29 muscle biopsies were subjected to la-
belling with SPA-HRPO (not used in three cases and not
reported in the remainder) and further studies are neces-
sary in order to better understand the pathophysiology of
this disease and to aid the diagnosis. However, until this
data is available, the following recommendations are of-
fered to maximise the chance of successful diagnosis: (1)
biopsy of end-stage muscles should be avoided as adipose
or connective tissue replaces muscle tissue and diagnosis
may be challenging, so clinicians should chose to biopsy
muscles which are not severely atrophied); (2) our data
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muscle, which was sampled in 22/29 (76%) of the present
cases and confirmed diagnosis in 19 cases; (3) lingual
muscle biopsy was performed in five cases for which bi-
opsy samples were collected and in two of these the pro-
cedure assisted in making a diagnosis, so this may also be
useful biopsy site and this procedure is especially indicated
when dogs are presented with oropharyngeal dysphagia;
(4) EMG and MRI were valuable in helping identify the ap-
propriate muscle to sample (Figure 6).
EMG has lower cost, but may not detect mild disease
especially if there is minimal involvement of the appen-
dicular muscle. MRI is generally more expensive to per-
form but where performed showed good association
with the histopathology results. In people, whole-body
MR imaging using rapidly acquired fat-suppressed Short
TI Inversion Recovery (STIR) sequences has been rec-
ommended to facilitate a global overview of the extent
and symmetry of muscle disease and to direct biopsy
collection. STIR signal intensity has been documented to
have a 97% specificity for identifying sites of inflamma-
tory myopathy that have been confirmed at biopsy [16]
[although, where previous corticosteroid treatment is
used, post-contrast images may be more helpful. Inflam-
matory muscle lesions on MR images were characterised
by diffuse and poorly marginated abnormal signal on
T1- and T2-weighted images, with marked enhancement
after contrast medium administration [16].
Other laboratory tests can be used to support a diagnosis
of VIP and rule out other diseases, as when making a diag-
nosis of VIP, other causes of myopathy should be ruled out.
The most important differential diagnoses are toxins [17],
endocrine disease [18-20] and infectious causes of inflam-
matory myopathy, especially Toxoplasma gondii, Neospora
caninum and in some geographical regions Leishmania,
Ehrlichia canis, Sarcocystis neurona and Hepatozoon amer-
icanum. A limitation of our study was the lack of com-
pleteness of such laboratory tests for many cases. However
it is noted that dysphagia and/or regurgitation are rarely re-
ported as clinical signs of inflammatory myopathy associ-
ated with infectious diseases. In a comprehensive literature
search [21-45] a single case report was found describing
dysphagia and regurgitation in a puppy with neonatal neos-
porosis that also presented with neuromuscular paralysis
[45]. It is not unusual for neospora tachyzoites to be found
in the oesophagus on histological examination of post mor-
tem material but more uncommon for there to be associ-
ated clinical signs and therefore the clinical significance is
uncertain [35,38]. Therefore, although infectious diseases
should be ruled out as an underlying cause in cases of sus-
pected VIP, it is a rare differential for adult dogs presenting
with dysphagia and regurgitation. Given the clinical presen-
tation of VIP, the most important differential diagnoses are
MMM and MG, which may also show similar clinicalfeatures to VIP. Thus, serum titres for antibodies against
type 2 M fibres and the acetylcholine receptor should be
evaluated. Occasionally a dog may present with both myas-
thenia gravis and VIP [46]. In our study MMM was not di-
agnosed in any of the affected dogs, although it should be
noted that only 38% of dogs were tested.
Marked elevation of CK is an indication of damage to
skeletal muscles; however, only 25 of the 47 dogs tested
had an elevation above 1000 IU/L. This may be because
generalised muscle disease was not a feature. In most
cases of VIP, the masticatory and pharyngeal muscles
were most severely affected and constituted only a small
volume of muscle mass compared with the whole body.
Of the 25 dogs with marked elevation of CK, 18 had
generalised muscle atrophy and/or exercise intolerance,
but seven were considered to be normal in this regard.
The most consistent clinical signs of VIP are dysphagia
and sialorrhea due to tongue, pharyngeal and oesophageal
dysfunction, and masticatory muscle atrophy. The canine
oesophageal anatomy differs from other species such as
cats and people, especially in the musculature of the
oesophageal body. In dogs the cranial oesophageal (crico-
pharyngeal) sphincter and the entire oesophageal body is
composed of striated muscle, while the caudal oesophageal
(gastroesophageal) sphincter is smooth muscle. Therefore
the canine oesophagus is often involved in diseases that
affect skeletal muscle [47]. However, in at least two of the
present series of cases there were alternative explanations
for the oesophageal involvement identified on post-
mortem examination: in one case there was no primary in-
flammatory process in oesophageal muscle, but there was
invasion of inflammatory cells secondary to degeneration
of myocytes and a second case revealed lymphoid cell infil-
tration of the oesophageal myenteric plexus with dimin-
ution in the number of ganglion cells, which may represent
a ganglionopathy. The latter histopathological picture is
similar to that observed in oesophageal achalasia in man
[48]. Oesophageal achalasia is characterised by dysfunction
of the lower oesophageal sphincter and derangement of
oesophageal peristalsis. The cause is not fully known, but
autoimmune processes appear to be involved in human pa-
tients with a genetic susceptibility to the disease [48].
The dysphagia reported in this case series may not be
entirely due to oesophageal dysfunction, as masticatory,
pharyngeal, and lingual muscle involvement could con-
tribute to difficulty eating. In this case series, atrophy of
the masticatory muscles was a common feature of the
disease. Polymyositis with masticatory muscle atrophy
and tongue involvement has been recognized previously
in Pembroke corgi dogs in which end-stage lingual atro-
phy was a predominant feature [49]. In the present
series, atrophy of the tongue was observed as an end-
stage of disease in three untreated dogs and in one clin-
ical history, the tongue was described as being shrivelled,
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as motor function. Sensory deficits could not be con-
firmed, however, the tongue is richly innervated and it is
theoretically possible that end-stage fibrosis might inter-
fere with nervous supply.
Perhaps surprisingly for a polymyopathy, exercise in-
tolerance was not the most common clinical sign, with
normal exercise ability being reported in 27 of 77 dogs
and only 33 of 77 dogs developed generalised muscle at-
rophy. Others have described the clinical presentation of
canine polymyositis being characterised by cervical
ventroflexion and dysbasia (a stiff gait with short stride
a.k.a. “walking on eggshells”); [9]. This was not a feature
of VIP. The lack of appendicular muscle involvement
coupled with an insidious onset of the disease may be a
reason for delayed or incorrect diagnosis.
Dysuria was a surprising clinical sign associated with a
skeletal muscle disease but was reported in three male
dogs with biopsy-confirmed VIP. The detrusor is smooth
muscle, so if detrusor myopathy was a cause of the dys-
uria then it would imply the presence of autoantibodies
against smooth as well as skeletal muscle, which would
be unlikely as in all human and laboratory animal
models of myositis, autoantibodies are specific to stri-
ated muscle and correlate with distinct clinical pheno-
types [50,51]. Additionally, an immune-mediated process
targeting smooth muscle would reasonably be expected
to result in intestinal and arterial smooth muscle disease
too. Immune-mediated damage of the skeletal muscle of
the external urethral sphincter is possible, although this
might have been expected to result in clinical signs of
sphincter mechanism incompetence. The possibility of a
neurological cause of dysuria cannot be excluded; how-
ever, an anatomical difference exists between the urethra
of female and male dogs, which may explain why dysuria
was present only in male dogs. Female urethral smooth
muscle occupies one-third of the volume of the vesical
neck (both the bladder neck and the urethral smooth
muscle constitute the internal urethral sphincter) and
one fourth of the volume of the proximal urethra, while
striated muscle is present in the distal half of the urethra
[52]. In contrast, the male urethral smooth muscle is as-
sociated mainly with the trabeculae surrounding the
prostate lobules and is fundamental for contraction of
the lobules (i.e. the bladder neck acts as smooth muscle
sphincter), while striated muscle is present caudal to the
prostate (post-prostatic urethra), which also overlaps the
caudal surface of the prostate gland [53]. Although we
need to consider that in this study fifty of the 77 affected
cases were male dogs, it can be speculated that the dys-
uria in male dogs with VIP may be associated with more
extensive involvement of urethral striated muscle.
An easier and more reliable method of detecting ca-
nine oesophageal dysmotility would be of great benefitbecause complications associated with dysphagia and as-
piration pneumonia are the main cause of death in VIP.
Deglutition consists of three phases: the oral phase that oc-
curs in the mouth and involves lips, tongue, teeth, and pal-
ate, and it is essential for the formation of the food bolus;
the pharyngeal phase that is essential for the progression
of the food bolus from the mouth to the oesophagus and
preventing entry into the airway and the oesophageal
phase that allows the food bolus to travel through the
oesophagus towards the stomach. Plain or contrast thor-
acic radiographs may reveal megaoesophagus; however,
if less severe or dynamic disease of the oesophagus is
present, fluoroscopy may be more useful, especially in the
detection of swallowing disorders that mainly involve the
oral and pharyngeal phase. However difficulties in per-
forming this test were reported either due to lack of equip-
ment or to the difficultly in keeping the animal steady for
the image intensifier. It is also advisable to perform these
studies with great care in order to avoid barium aspiration
pneumonia. In man, oesophageal manometry is considered
the ‘gold standard’ for assessing oesophageal motor func-
tion and is used to measure the pressures and the pattern
of muscle contractions in the oesophagus, and to detect
abnormalities in the contractions and strength of the
oesophageal muscle and its sphincter [54]. Over the last
few years intraluminal oesophageal manometry has de-
veloped into high-resolution manometry, which improves
acquisition of data, and the method of displaying and ana-
lysing the data using oesophageal pressure topography
plots. This new technology is also patient-friendly as it al-
lows for a shorter procedure time, and it is much easier to
use and to interpret compared with conventional manom-
etry [55]. High-resolution manometry could be useful in
the detection of oesophageal disorders in animals, but
further studies are required to confirm this. Previously
the majority of the veterinary studies have used con-
ventional manometry, and most of them used anaesthe-
tised dogs [56-61].
The presence of Helicobacter spp. in two dogs and
inflammatory bowel disease (IBD) in eight dogs that
underwent oesophagogastroduodenoscopy was considered
incidental to the primary diagnosis of VIP. Helicobacter
spp. have been associated with chronic superficial gastritis
in man and play a role in the pathogenesis of peptic ulcer
disease, gastric carcinoma and lymphoma, but their clin-
ical significance in companion animals is not clear [62].
The finding of IBD could be more significant, especially
when the breed appears predisposed to other immune-
mediated diseases including MG, MMM, atopy, sebaceous
adenitis, keratoconjunctivitis sicca, steroid-responsive
meningitis arteritis, and immune-mediated polyarthritis
(Table 2). Vizslas have been also reported anecdotally to
be predisposed to immune-mediated haemolytic anaemia
[63] and immune-mediated thrombocytopenia [64]. There
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and polymyositis [65]. The disruption of the tight junc-
tions between enterocytes plays an important role in the
pathophysiology of IBD, altering the intestinal epithelial
barrier function and causing increased intestinal perme-
ability. The ‘leaky gut’ may then lead to translocation of
bacteria and endotoxin, which drives the intestinal inflam-
mation. A normal response from the immune system
should deal with the insult. However, in some individuals
this normal response may be defective, increasing the risk
of developing IBD, coeliac disease and possibly myositis
[65]. When investigating VIP, we therefore recommend
that comorbidities are looked for and treated if identified.
VIP is assumed to be an autoimmune disease because
of the response to immunosuppressive treatment. The
cornerstone of the treatment is glucocorticoid therapy
due to its short-term tolerability, cost effectiveness, and
clinical effectiveness [66]. Particular care however must
be taken if there is a risk of aspiration pneumonia as the
adverse effects of polydipsia, polyphagia and immuno-
suppression increases the likelihood of this potentially
fatal complication. As the individual treatment plans for
the dogs in this study varied, it was not possible to make
firm conclusions regarding treatment, but the trends
suggested the following: (1) early diagnosis improves the
chance of successful treatment; (2) therapy should be ta-
pered slowly with time of tapering depending on clinical
signs. We do not have enough data to strongly deter-
mine the dosage and the length of the treatment pro-
tocol for the VIP, however inadequate corticosteroid
dosage i.e. anti-inflammatory dose or a rapid tapering
regimen with withdrawal of drugs within a 1-year period
appeared to be associated with earlier relapse and in-
creased mortality in 23% of the treated cases. The opti-
mal glucocorticoid dosing regimen is not well defined
[13]; however, as a general rule we would suggest the
following: 2 mg/kg once a day for 2 weeks, then 1 mg/kg
once a day for 4 weeks, then 0.5 mg/kg once a day for
10 weeks, then 0.25 mg/kg once a day for 16 weeks, then
0.25 mg/kg every other day for 16 weeks then continue
to withdraw over a further 2–4 weeks; (3) close monitor-
ing is required and the drugs are tapered on the basis of
clinical signs and the concentration of serum CK, if this
test had shown abnormal result prior treatment.
In four dogs, dysphagia and regurgitation prevented
the use of oral therapy, but there was a good response to
initial parenteral short-term corticosteroid therapy such
as with dexamethasone and prednisone acetate. Other
parental corticosteroids such as methylprednisolone
seemed to be less effective (two cases), however the dif-
ficulty of comparing different treatments used is a limita-
tion of this paper and further study is needed to
establish the most effective therapeutic protocol for this
disease. This study also suggested that a treatment basedon a combination of immunosuppressive agents was pref-
erable to reduce long-term corticosteroid side effects such
polyphagia, polydipsia, polyuria, and iatrogenic hyperadre-
nocorticism, reduce the risk of aspiration pneumonia and/
or when the clinical response to monotherapy was poor.
The most common and successful drug used in addition
to corticosteroids was azathioprine; however a well-
designed prospective trial needs to be performed evaluat-
ing different treatments. The dosage of azathioprine used
but we would suggest 2 mg/kg once a day for up to ten
days, then 2 mg/kg every other day thereafter. Although
our study cannot assess the most effective treatment
protocol, we would advise that this dosage should be
maintained for a month beyond the cessation of prednisol-
one. Again this regimen should be adjusted on the basis of
assessment of both clinical response and serum CK levels.
To reduce the risk of aspiration pneumonia and to aid
swallowing dogs should be fed from a height and with
small meals 4–6 times daily. Some foods are easier to
swallow than others and our experience is that individually
feeding small walnut-size balls of firm, but slippery-
textured commercial food with a high protein and fat
content is the most useful. This should be coupled with
coupage after feeding in order to encourage belching and
help to prevent aspiration. In some cases an anti-gulping
bowl (Dogit® Go Slow Anti-Gulping Dog Bowl, Rolf C.
Hagen Ltd., West Yorkshire, UK) can be useful, especially
in dogs with polyphagia due to high dosage of corticoste-
roids. In cases where the megaoesophagus impedes the
propulsion of the food bolus, we recommend the use of
the Bailey chair in order to maintain a truly vertical
oesophageal position and reduce the risk of aspiration
pneumonia.
Immune-mediated diseases are thought to develop
through a complex combination of genetic and environ-
mental factors and have been associated with variants of
MHC class I or II genes, which in the dog are referred to as
the dog leukocyte antigen (DLA) system. The MHC mole-
cules control the immune system’s recognition of self and
non-self-antigens. Class II molecules are involved in pre-
senting antigens to CD4+ T cells (T helper cells) [67]. CD4+
T cells play a key role in regulating immune system func-
tion with a subset of immunoregulatory cells (CD25+CD4+)
suppressing proliferation of other immune cells, especially
CD25−CD4+ T cells and CD8+ T cells [68]. The basis of
autoimmune reactions is the failure of this immunoregula-
tory T cell to properly control other immune cells and
down-regulate the immune response. In polymyositis, in-
flammatory cells, including T cells and macrophages, are
concentrated in the endomysium and surround and invade
non-necrotic fibres [6]. Classically there are more CD8+ T
cells than CD4+ T cells; however, Haley and others reported
that cellular infiltrates in two dogs withVIP were composed
predominantly of CD4+T cells with fewer CD8+T cells [13].
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creased on the sarcolemma and on the membrane of infil-
trating cells in Haley and others study, however the
assessment of this in our biopsies was not undertaken and
needs to be considered in future studies to further help elu-
cidate the pathogenesis of VIP.
Genes within the MHC are unusual because they are
highly polymorphic, meaning that there are many allelic
variations. This degree of variation most likely improves
survival against infectious diseases. However in the dog,
selective inbreeding has led to a restriction of DLA haplo-
types in many breeds, which in turn influences susceptibil-
ity to infectious diseases and also to immune-mediated
conditions [69]. Our group investigated DLA class II asso-
ciations from 212 Hungarian Vizsla dogs, which were
stratified both on disease status and degree of relatedness
to an affected dog. One haplotype, DLA-DRB1*02001/
DQA1*00401/DQB1*01303, had a significantly raised fre-
quency in cases compared with controls. A single copy of
the risk haplotype was sufficient to increase disease risk,
with the risk substantially increasing for homozygotes.
There was a trend of increasing frequency of this haplo-
type with degree of relatedness, indicating a low disease
penetrance and suggesting involvement of other genetic
and environmental factors [70]. Further genetic studies are
required; however, our immediate advice to breeders wish-
ing to reduce the risk of VIP is that a bitch should only be
mated to a dog when the inbreeding coefficient (CoI) of
the resulting puppies, as measured from a five generation
pedigree, is less than 12.5% [71]. The CoI is the probability
of homozygosity by descent, and it ranges from 0% to
100%. In other words, the lower the inbreeding coefficient,
the lower the probability of homozygosity with a CoI of
over 25% being the equivalent of a mother/son mating.
The mean CoI in Vizsla Breed is 5.1% [72, 73]; however,
the average CoI of 77 of the 79 dogs in our study of
Vizslas was 16.3% (range: 2.5% - 40.7%). However it
should be remembered that having a low CoI will not pro-
tect against VIP and breeding of dogs with immediate rel-
atives with VIP should be avoided.
Conclusions
The Hungarian Vizsla has an inherited predisposition
to a form of inflammatory polymyopathy. The most
common clinical signs are dysphagia, sialorrhea, masti-
catory muscle atrophy, and regurgitation. The mainstay
of treatment is immunosuppressive therapy in addition
to feeding therapy designed to meet individual needs.
Early diagnosis, careful monitoring and slow with-
drawal of medication improves prognosis. To improve
diagnosis the feasibility of other diagnostics techniques
such as a high resolution manometry should be investi-
gated. Further genetic and immunological studies will bet-
ter define VIP; however, until then reducing inbreeding inorder to minimise homozygosity of the risk haplotype is
recommended.Methods
Our retrospective cohort study was based on 369 med-
ical records of Hungarian Vizsla dogs. The records were
collected from dogs from which DNA had been submit-
ted to the Centre for Integrated Genomic Medical Re-
search (CIGMR, University of Manchester, UK) between
1992 and 2013. Cases had been recruited following a na-
tionwide appeal for Hungarian Vizslas affected with
polymyositis and their affected or unaffected relatives
[74-76]. Details of the phenotype were generated for
each case [77], stating Kennel Club registration number,
pedigree name, common name, coat colour, gender, age,
and weight. It also indicated clinical signs, diagnostic
tests performed, and treatment. Based on certainty of
diagnosis of VIP the cases were divided into two groups.
Inclusion criteria for Group 1 were clinical signs and
histopathology findings compatible with an inflamma-
tory polymyopathy. Inclusion criteria for Group 2 was
clinical signs of neuromuscular disease including pres-
ence of dysphagia, sialorrhea, temporal muscle atrophy,
elevated serum creatine kinase (CK) activity, and suffi-
cient clinical history to suggest that other neuromuscular
disorders could be ruled out. This group also included
dogs where muscle biopsy or post-mortem had been per-
formed confirming a myopathy, but with no evidence of
an inflammatory cell infiltrate. Pedigrees from dogs of all
of the affected families were researched and collated, and
a pedigree database was created. In order to investigate
the genetic basis of this disorder, DNA was extracted from
blood in excess of that required for diagnostic tests. Alter-
natively, oral swabs were submitted to the CIGMR in
order to investigate the genetic basis of this disorder [70].
This is a non-experimental study based on a retrospect-
ive analysis of necessary diagnostic results and clinical his-
tory for which there was full owner written consent.Additional files
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